Amedisys Future Growth
Future criteria checks 3/6
Amedisys wird ein jährliches Wachstum der Erträge und Einnahmen um 67.8% bzw. 5.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich grow um 72.5% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.6% betragen.
Key information
61.6%
Earnings growth rate
61.7%
EPS growth rate
| Healthcare earnings growth | 12.4% |
| Revenue growth rate | 5.4% |
| Future return on equity | 13.3% |
| Analyst coverage | Good |
| Last updated | 26 Mar 2024 |
Recent future growth updates
Recent updates
Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?
Apr 10
Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?
Feb 25Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around
Feb 10At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?
Jan 03A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)
Dec 16Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal
Nov 12Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?
Sep 19An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued
Sep 04Amedisys: ROIC, Tangible Book Value Each Softening
Aug 24Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement
Aug 04Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates
Jul 27We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt
Jul 20At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?
Jun 04Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled
May 05Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?
Apr 20Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?
Apr 06Is Amedisys (NASDAQ:AMED) A Risky Investment?
Feb 20Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue
Jan 19Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?
Dec 03These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely
Nov 18Amedisys (NASDAQ:AMED) Could Easily Take On More Debt
Aug 18Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)
Jul 23Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity
Jul 18Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive
Jun 28It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package
Jun 02Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?
May 24Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)
Apr 14Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,627 | 159 | N/A | N/A | 1 |
| 12/31/2025 | 2,497 | 155 | 180 | 167 | 11 |
| 12/31/2024 | 2,336 | 144 | 159 | 152 | 14 |
| 12/31/2023 | 2,236 | -10 | 124 | 137 | N/A |
| 9/30/2023 | 2,228 | 3 | 105 | 118 | N/A |
| 6/30/2023 | 2,229 | 2 | 101 | 114 | N/A |
| 3/31/2023 | 2,234 | 112 | 103 | 111 | N/A |
| 12/31/2022 | 2,223 | 119 | 126 | 133 | N/A |
| 9/30/2022 | 2,220 | 121 | 91 | 98 | N/A |
| 6/30/2022 | 2,216 | 140 | 166 | 173 | N/A |
| 3/31/2022 | 2,222 | 191 | 177 | 184 | N/A |
| 12/31/2021 | 2,214 | 209 | 182 | 189 | N/A |
| 9/30/2021 | 2,206 | 220 | 242 | 250 | N/A |
| 6/30/2021 | 2,196 | 247 | 264 | 271 | N/A |
| 3/31/2021 | 2,117 | 202 | 331 | 337 | N/A |
| 12/31/2020 | 2,072 | 184 | 284 | 289 | N/A |
| 9/30/2020 | 2,021 | 166 | 294 | 298 | N/A |
| 6/30/2020 | 1,972 | 128 | 256 | 263 | N/A |
| 3/31/2020 | 1,980 | 127 | 180 | 188 | N/A |
| 12/31/2019 | 1,956 | 127 | 194 | 202 | N/A |
| 9/30/2019 | 1,889 | 127 | 184 | 191 | N/A |
| 6/30/2019 | 1,812 | 124 | 204 | 212 | N/A |
| 3/31/2019 | 1,731 | 123 | 197 | 203 | N/A |
| 12/31/2018 | 1,663 | 119 | 217 | 223 | N/A |
| 9/30/2018 | 1,626 | 88 | 184 | 192 | N/A |
| 6/30/2018 | 1,583 | 71 | 128 | 133 | N/A |
| 3/31/2018 | 1,546 | 42 | 111 | 119 | N/A |
| 12/31/2017 | 1,511 | 30 | 95 | 106 | N/A |
| 9/30/2017 | 1,474 | 43 | N/A | 102 | N/A |
| 6/30/2017 | 1,456 | 40 | N/A | 99 | N/A |
| 3/31/2017 | 1,438 | 46 | N/A | 77 | N/A |
| 12/31/2016 | 1,419 | 37 | N/A | 62 | N/A |
| 9/30/2016 | 1,391 | 41 | N/A | 54 | N/A |
| 6/30/2016 | 1,358 | 38 | N/A | 78 | N/A |
| 3/31/2016 | 1,313 | 38 | N/A | 106 | N/A |
| 12/31/2015 | 1,266 | -3 | N/A | 108 | N/A |
| 9/30/2015 | 1,230 | -7 | N/A | 92 | N/A |
| 6/30/2015 | 1,204 | -7 | N/A | 87 | N/A |
| 3/31/2015 | 1,193 | -10 | N/A | -45 | N/A |
| 12/31/2014 | 1,188 | 13 | N/A | -66 | N/A |
| 9/30/2014 | 1,191 | -4 | N/A | -62 | N/A |
| 6/30/2014 | 1,192 | -103 | N/A | -59 | N/A |
| 3/31/2014 | 1,203 | -109 | N/A | 64 | N/A |
| 12/31/2013 | 1,233 | -93 | N/A | 102 | N/A |
| 9/30/2013 | 1,278 | -191 | N/A | 109 | N/A |
| 6/30/2013 | 1,340 | -90 | N/A | 103 | N/A |
Analyst Future Growth Forecasts
Einkommen vs. Sparrate: AMED wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.3%).
Ertrag vs. Markt: AMED wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: AMED wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: AMEDDie Einnahmen des Unternehmens (5.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.1% pro Jahr).
Hohe Wachstumseinnahmen: AMEDDie Einnahmen des Unternehmens (5.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Earnings per Share Growth Forecasts
Future Return on Equity
Künftige Eigenkapitalrendite: AMEDDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12.6%).